Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• DNA damage response (DDR) defects promote tumor formation and mutations.
• Synthetic lethality therapies exploit DDR deficiencies, with PARP inhibitors (e.g., olaparib) being a prime example for BRCA-mutated cancers.
• This has spurred research into other DDR pathway components as therapeutic targets.

Purpose of the Study:

• To review recent advancements in the development of DDR kinase inhibitors.
• To highlight inhibitors in preclinical and clinical stages targeting DDR signaling pathways.
• To elucidate the biological functions of key DDR genes and proteins.

Main Methods:

• Literature review of preclinical and clinical studies on DDR kinase inhibitors.
• Analysis of crystal structures of DDR enzymes and inhibitor binding modes.
• Summary of the biological roles of ATR, DNA-PK, ATM, PARP, CHK1, and WEE1.

Main Results:

• Numerous DDR kinase inhibitors have been identified, with several showing promise in clinical trials.
• Understanding of DDR enzyme structures and inhibitor interactions is advancing.
• Key DDR proteins like ATR, DNA-PK, ATM, PARP, CHK1, and WEE1 are crucial in cancer development and therapeutic targeting.

Conclusions:

• DDR kinase inhibitors represent a promising avenue for synthetic lethality-based cancer therapies.
• Ongoing research and clinical trials are vital for translating these discoveries into effective treatments.
• Targeting the DDR pathway offers a strategic approach to combat various cancers.